Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects

Diabetes Care

Volumn 25, Issue 12, 2002, Pages 2123-2128

  Cefalu, William T ^a   Schneider, David J ^a   Carlson, Harold E ^b   Migdal, Phyllis ^b   Lim, Leonil Gan ^b   Izon, Meriam P ^b   Kapoor, Anoop ^c   Bell Farrow, Audrey ^d   Terry, James G ^d   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BODY FAT; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; GLUCOSE TOLERANCE TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FIBRINOLYSIS; GLIPIZIDE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RESEARCH DESIGN;

EID: 0242686414     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.12.2123     Document Type: Article

References (37)

1. Serrano RM: Epidemiology of cardiovascular disease in type 2 diabetes. Int J Clin Pract Suppl 4-7, 2001
2. Howard BV, Magee MF: Diabetes and cardiovascular disease. Curr Atheroscler Rep 2:476-481, 2000
3. Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 342:1040-1042, 2000
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
5. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE: Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 53:538-549, 2002
6. Goldberg RB: Cardiovascular disease in diabetic patients. Med Clin North Am 84:81-93, 2000
7. Marks JB, Raskin P: Cardiovascular risk in diabetes: a brief review. J Diabetes Complications 14:108-115, 2000
8. Reaven GM: Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 4 (Suppl. 1):13-18, 2002
9. Schneider DJ, Sobel BE: The coagulation and fibrinolytic systems, diabetes, and the heart: therapeutic implications for patients with type 2 diabetes. In Diabetes and Heart Disease. New York, Marcel Dekker, Inc., 2002, In press
10. Sobel BE: The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians 111:313-318, 1999
11. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97:2213-2221, 1998
12. Sobel BE: Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 99:2496-2498, 1999
13. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91:764-770, 1995
14. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ: Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47:290-293, 1998
15. Chen Y, Schneider DJ: The independence of signaling pathways mediating increased expression of plasminogen activator inhibitor type 1 in HepG2 cells exposed to free fatty acids or triglycerides. Int J Exp Diabetes Res. In press
16. Chen Y, Billadello JJ, Schneider DJ: Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol 20:2696-2701, 2000
17. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 13:1822-1828, 1993
18. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
19. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UK-PDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012, 1999
20. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
21. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 108 (Suppl. 6a):15S-22S, 2000
22. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
23. Burge MR, Schmitz-Fiorentino K, Fischette C, Quails CR, Schade DS: A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 279:137-143, 1998
24. Cefalu WT, Bell-Farrow AD, Wang ZQ, McBride D, Dalgleish D, Terry JG: Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Dev Res 44:1-7, 1998
25. Cefalu WT, Werbel S, Bell-Farrow AD, Terry JG, Wang ZQ, Opara EC, Morgan T, Hinson WH, Crouse JR: Insulin resistance and fat patterning with aging: relationship to metabolic risk factors for cardiovascular disease. Metabolism 47:401-408, 1998
26. Wolfe RR: Radioactive and stable isotope tracers in biomedicine. In Principles and Practice of Kinetic Analysis. New York, Wiley Liss, 1992, p. 283-315
27. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P: Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 22:312-317, 1998
28. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I: Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49:1374-1380, 2000
29. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110, 1996
30. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997
31. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE: Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49:633-639, 2000
32. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I: Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96:761-768, 1997
33. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109, 1994
34. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H: No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 67:117-120, 1992
35. Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS: Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 47:637-643, 1998
36. Kato K, Yamada D, Midorikawa S, Sato W, Watanabe T: Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 49:662-665, 2000
37. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996